United States Trending Tech Markets Politics Business Science Memes

Sutro Biopharma on August 12, 2022

Balanced News

Q3 2022 Earnings Estimate for Sutro Biopharma, Inc. (NASDAQ:STRO) Issued By Jefferies Financial Group - MarketBeat

Sutro Biopharma, Inc. (NASDAQ:STRO - Get Rating) - Equities research analysts at Jefferies Financial Group decreased their Q3 2022 EPS estimates for shares of Sutro Biopharma in a research note issued on Wednesday, August 10th. Jefferies Financial Group analyst R. Song now anticipates that the company will earn ($0.93) per share for the quarter, down from their previous forecast of ($0.91). The consensus estimate for Sutro Biopharma's current full-year earnings is ($3.27) per share. Jefferies Financial Group also issued estimates for Sutro Biopharma's Q4 2022 earnings at ($0.95) EPS, FY2022 earnings at ($3.63) EPS, FY2023 earnings at ($3.30) EPS, FY2024 earnings at ($3.17) EPS, FY2025 earnings at ($3.99) EPS and FY2026 earnings at ($1.98) EPS.

marketbeat.com Aug 12, 2022

Market Forecasts

Bullish / Bearish

Digital Assets / Most Accurate

Trading Strategies

Long Volatility

Short Volatility

Balanced News

Balanced News / Sources

Tech / Memes / Politics

About

About / Pricing / Forum

Contact Helium Trades

2024 © Helium Trades
Privacy Policy & Disclosure

* Disclaimer: Nothing on this website constitutes investment advice, performance data or any recommendation that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. Helium Trades is not responsible in any way for the accuracy of any model predictions or price data. Any mention of a particular security and related prediction data is not a recommendation to buy or sell that security. Investments in securities involve the risk of loss. Past performance is no guarantee of future results. Helium Trades is not responsible for any of your investment decisions, you should consult a financial expert before engaging in any transaction.